CD4 and Kaposi's sarcoma: After controlling for CD4+ cell count, adult on HAART had a significantly lower risk of oral Kaposi's sarcoma compared with those not on HAART (adjusted OR = 0.29; 95% CI = 0.10–0.89; p < 0.03).